Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus, Inc. (NASDAQ: EOLS) will release its third quarter 2022 financial results on November 8, 2022, after U.S. market close. A conference call will follow at 4:30 p.m. ET, allowing stakeholders to discuss the outcomes and participate in a Q&A session. Interested parties can join via phone at (877) 407-6184 for U.S. or (201) 389-0877 for international calls, or access the live webcast on the Evolus website. A replay will also be available post-call.
Evolus, Inc. (NASDAQ: EOLS) has initiated its commercial operations in Great Britain, marking a significant milestone in its global expansion strategy. The company has shipped its first orders for Nuceiva® (botulinum toxin type A), targeting the UK's largest aesthetic neurotoxins market. Evolus will also launch in Germany and Austria later in 2023 and aims for further European expansion. The company’s commitment to education for healthcare professionals is evident through its Innovator and Early Adopter programs, designed to enhance product understanding and application.
Evolus, Inc. (NASDAQ: EOLS) concluded certain royalty payments from a 2021 settlement with Medytox and Allergan, marking a significant milestone for the company's financial profile. CEO David Moatazedi reported expectations for improved profit margins and a robust growth outlook for 2022. The company anticipates an adjusted gross profit margin increase to 68%-71% for Q4 2022, up from 57.4% in Q2 2022. Additionally, Evolus plans to launch Nuceiva in Europe and is set to present preliminary data from a Phase II study in early 2023.
Evolus, Inc. (NASDAQ: EOLS) announced stock options and restricted stock units (RSUs) granted to Sandra Beaver, the new Chief Financial Officer, on September 5, 2022. These include 169,158 stock options with an exercise price of $9.06 and 36,443 RSUs. The options vest over four years, with 25% vesting annually. This grant complies with Nasdaq Listing Rule 5635(c)(4), emphasizing the company's commitment to attracting and retaining talent. Evolus focuses on innovative beauty products and the aesthetic neurotoxin market through its flagship product, Jeuveau®.
Evolus, Inc. has appointed Sandra Beaver as its new Chief Financial Officer, effective September 5, 2022. With over 20 years of financial expertise, Beaver previously served as Senior Vice President of Finance at Experian, overseeing significant revenue responsibilities. Her experience includes roles at International Game Technology where she led financial planning and analysis. President and CEO David Moatazedi highlighted her potential to enhance Evolus' growth and market share, particularly in the U.S. and Europe.
Evolus, Inc. (NASDAQ: EOLS), a leading performance beauty company, will participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. The event will feature members of its management team, with an audio webcast available on demand starting at 7:00 am ET. Evolus focuses on innovative products tailored for beauty consumers, highlighting its flagship product, Jeuveau®, which is dedicated exclusively to aesthetics. More details are available on Evolus' website.
Evolus, Inc. (NASDAQ: EOLS) announced promising results from a peer-reviewed analysis showing that male patients treated with Jeuveau® achieved approximately 10% higher responder rates compared to those receiving BOTOX® in a Phase III trial. The analysis, involving 56 males, indicated a consistent trend favoring Jeuveau® despite not reaching statistical significance due to the small sample size. The increasing popularity of botulinum toxin treatments among men, which rose by 380% from 2000 to 2018, highlights the market potential for Jeuveau® in this demographic.
Evolus, Inc. (NASDAQ: EOLS) reported a 42% increase in Q2 2022 net revenue to $37.2 million, driven by higher volumes and a greater average selling price of Jeuveau®. The company anticipates achieving the upper end of its full-year 2022 guidance of $143 to $150 million, with projected year-over-year growth of nearly 50%. Evolus is set to launch Nuceiva® in Europe in Q3 2022 and maintains a strong cash position of $84.5 million. However, operating expenses rose to $58.5 million, resulting in a loss from operations of $21.3 million.
Evolus, Inc. (NASDAQ: EOLS) will announce its second quarter 2022 financial results on August 2, 2022, before U.S. markets open. A conference call will be held at 9:00 a.m. ET to discuss the results, followed by a Q&A session. Investors can participate by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or via a live webcast accessible on Evolus' website. A replay of the call will be available afterwards. Evolus focuses on the aesthetic neurotoxin market, primarily with its product Jeuveau, designed for beauty consumers.
Evolus (NASDAQ: EOLS) has launched its largest consumer engagement program, "Switch Your Tox and Love Evolus Forever," aimed at increasing adoption of its neurotoxin product, Jeuveau®. The campaign offers $160 off treatments for new patients at participating practices, starting September 1. This initiative includes incentives for injectors, such as product discounts and marketing support. Since its launch, Jeuveau has been administered in approximately 2 million treatments, highlighting the demand for the product in the aesthetic market.